# Signals Article: Putative Target Q16617 for Visceral Leishmaniasis Therapeutic Development
Background
Visceral leishmaniasis (VL), also known as kala-azar, is a severe form of leishmaniasis caused by the protozoan parasite Leishmania donovani. It is characterized by prolonged fever, weight loss, anemia, and splenomegaly, and can be fatal if left untreated. Current treatment options are limited and often associated with significant side effects, leading to a pressing need for new therapeutic targets. A putative target candidate, Q16617, has emerged from recent data-mining efforts, suggesting its potential role in VL pathogenesis and warranting further investigation.Data-mining rationale
The identification of Q16617 as a putative target was derived from a comprehensive analysis of UniProt's reviewed human entries for "visceral leishmaniasis," cross-referenced against 17 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate Q16617 appeared in several expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical program. This absence indicates an opportunity for further exploration of its therapeutic potential. Additionally, many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, suggesting that a re-analysis could yield more robust insights.Why prior analyses may have missed this
Prior analyses may have overlooked the significance of Q16617 due to several factors. The datasets analyzed were generated using older statistical methodologies that may not have adequately controlled for multiple testing, potentially obscuring the identification of differentially expressed genes. Furthermore, the complex interactions between Leishmania parasites and host immune responses may have diluted the signal for specific targets in earlier studies. The absence of a clinical program for Q16617 further suggests that its therapeutic potential has not been fully explored in the context of visceral leishmaniasis.Reasoning for further validation
To validate the potential of Q16617 as a therapeutic target for visceral leishmaniasis, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to re-analyze the matched GEO datasets, which may reveal more accurate differential expression results. 2. **Validate Differentially-Expressed Genes**: Conduct quantitative PCR (qPCR) validation of the top differentially expressed genes identified in the re-analysis using an independent cohort to confirm their relevance in VL infection. 3. **Check Tissue Specificity**: Investigate the tissue specificity of Q16617 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a therapeutic target. 4. **Pathway Context Analysis**: Employ STRING or OmniPath databases to explore the biological pathways associated with Q16617, providing context for its role in VL pathogenesis. 5. **Assess Druggability**: If Q16617 is validated as a relevant target, evaluate its druggability using databases such as DGIdb and ChEMBL to identify potential small molecules or compounds that could be developed into therapeutics.References
- UniProt: Q16617
- GEO Datasets: GDS:200146908, GDS:200140799, GDS:200134661, GDS:200118460, GDS:200125993